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Viral hepatitis is a leading cause of morbidity and mortality worldwide, but has long been neglected 
by national and international policymakers. Recent modelling studies suggest that investing in the 
global elimination of viral hepatitis is feasible and cost-effective. In 2016, all 194 member states of 
the World Health Organization endorsed the goal to eliminate viral hepatitis as a public health threat 
by 2030, but complex systemic and social realities hamper implementation efforts. This paper 
presents eight case studies from a diverse range of countries that have invested in responses to viral 
hepatitis and adopted innovative approaches to tackle their respective epidemics. Based on an 
investment framework developed to build a global investment case for the elimination of viral 
hepatitis by 2030, national activities and key enablers are highlighted that showcase the feasibility 
and impact of concerted hepatitis responses across a range of settings, with different levels of 
available resources and infrastructural development. These case studies demonstrate the utility of 
taking a multipronged, public health approach to: (1) evidence-gathering and planning; (2) 
implementation; and (3) integration of viral hepatitis services into the Agenda for Sustainable 
Development. They provide models for planning, investment, and implementation strategies for 
other countries facing similar challenges and resource constraints. 
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Key points  
 Viral hepatitis is the 6th leading cause of death globally, surpassing all other chronic 
infectious diseases including HIV, tuberculosis and malaria 
 Elimination of viral hepatitis as a public health threat is achievable; all WHO member 
countries endorsed this goal formally in 2016 
 Planning, implementation, and integration of national responses to viral hepatitis is ongoing, 
and many countries have adopted innovative approaches to address the diverse challenges 
of this endeavour in their local contexts 
 Existing approaches demonstrate that investing in viral hepatitis is affordable and cost-
effective, provides multisectoral cost-benefits, and alleviates the human burden of the 





Viral hepatitis contributes substantially to the global burden of disease, with 248 million people 
infected with hepatitis B and 71 million infected with hepatitis C worldwide.1 If left untreated, 
chronic viral hepatitis can cause life-threatening complications, such as cirrhosis and hepatocellular 
carcinoma.2 Despite this, the public health consequences of viral hepatitis have long been 
neglected.1 In contrast to the progress in combating many other communicable diseases in recent 
years, viral hepatitis-related morbidity and mortality continue to rise.1, 3 In 2010 viral hepatitis was 
the 10th leading cause of death, but by 2015, with 1.2 million deaths, it had overtaken HIV, malaria 
and tuberculosis to rise to 6th.4 Most viral hepatitis deaths are avertable through increased access to 
prevention, diagnosis, and treatment.  
In areas of high hepatitis B endemicity (e.g. Southeast Asia and sub-Saharan Africa), perinatal 
mother-to-child transmission (MTCT) and horizontal transmission during childhood are the most 
common routes of infection, while sexual contacts, unsafe injecting practices, and unhygienic 
medical or cosmetic procedures drive transmission elsewhere.5-7 Risk of developing chronic hepatitis 
B infection is inversely related to age at infection: around 90% of infants infected perinatally develop 
chronic infection, unless vaccinated at birth. This risk decreases to around 30% among children 
infected before the age of six years and to less than 5% of persons infected as adults.8-10 
The hepatitis C epidemic is similarly geographically diverse and mode of transmission differs 
substantially between regions.11-14 Globally, an estimated 52% of people who inject drugs (PWID) are 
hepatitis C antibody positive.15 Lack of access to needle and syringe programs (NSPs) and opioid 
antagonist treatment (OAT) result in unsafe injecting practices, which are the major route of 
transmission in high-income countries.15, 16 In low- and middle-income countries, additional 
transmission occurs in healthcare settings through substandard infection control practices.17  
In 2016, the 69th World Health Assembly adopted the Global Health Sector Strategy on Viral 
Hepatitis (GHSSH) 2016–2021. The strategy outlines five synergistic prevention and treatment 
service coverage targets to achieve the elimination of viral hepatitis as a public health threat by 2030 
(defined as 90% reduction in incidence and 65% in mortality, see Table 1).18 Implementation of the 
strategy is expected to strengthen health systems while enabling progress toward the United 
Nations’ Sustainable Development Goal (SDG) 3 target of universal health coverage.19, 20 Modelling 
studies suggest that rapid investment in diagnostic, prevention, and treatment services could 
achieve the World Health Organization (WHO) targets by 2030.21, 22 
How can viral hepatitis be eliminated by 2030? 
Eliminating viral hepatitis requires substantial investments in health systems strengthening and the 
full continuum of hepatitis services.18 Investing in the prevention and treatment of viral hepatitis 
provides many direct, indirect and cross-sectoral economic benefits through saving lives and 
alleviating the cost burden of disease to the individual, their families, and the state.23-26 To achieve 
elimination at a national level, the country-specific context and its unique challenges must be 
considered. A multipronged approach comprising three main pillars is most effective in addressing 
the local context; comprising (1) evidence-gathering and planning the response; (2) implementation 
of disease-specific activities, including investments in the delivery of care; and (3) integration of the 
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viral hepatitis response into SDG 3 by adopting a public health approach and embedding services 
into universal health coverage. 27  
The necessary tools for viral hepatitis elimination are already available, but worldwide 
implementation of a concerted viral hepatitis response is slow and faces many challenges. These 
include low levels of investments in health overall; inadequate data and weak surveillance systems; 
poor infrastructure; low awareness among policymakers, at-risk populations and primary care 
practitioners; high prices of some diagnostics and treatments; and a lack of prioritisation of viral 
hepatitis.28, 29 While most countries are on track to meet the WHO’s 2030 target of <0.1% Hepatitis B 
surface antigen (HBsAg) prevalence among 5-year-olds, without substantial further investments this 
target is currently unachievable for 20 countries, mainly in Africa and the Western Pacific. Moreover, 
only 12 countries are currently on track to achieve the hepatitis C elimination goal that all WHO 
member states adopted in 2016.30    
We have developed a Viral Hepatitis Investment Framework outlining the resourcing required to 
achieve elimination, the cost of the elimination of viral hepatitis globally, and methods for countries 
to address existing challenges.31 The Viral Hepatitis Investment Framework highlights key enablers to 
support a comprehensive viral hepatitis response and outlines priority national and international 
activities to maximise return on investment (Figure 1). Using the structure of the Investment 
Framework, this paper presents case studies from diverse countries (Table 2) that are successfully 
implementing innovative strategies to eliminate viral hepatitis (see Table 3). Additional case studies 
listed in Table 3 are summarised in the Appendix (Table 5 and figures 5, 6 and 7). 
Evidence-gathering and planning  
Low-quality surveillance systems and a lack of reliable cause-specific mortality data limit countries’ 
capacity to guide, implement, and monitor effective viral hepatitis responses.32, 33 To advocate for an 
adequate allocation of domestic resources and to mobilise external funding support, countries 
should develop a national plan that sets ambitious but achievable targets, informed by a robust local 
investment case for viral hepatitis. Gathering accurate data to inform a targeted approach can 
improve the cost-effectiveness of specific interventions.34-36 Since the launch of the GHSSH 2016-
2021, more countries have developed national hepatitis plans1 and both local and global investment 
cases for the elimination of viral hepatitis have been built.31, 35, 37 Many countries have begun 
collecting epidemiological data through national seroprevalence surveys or by adding key hepatitis 
indicators into existing surveillance systems. Below, we give examples of countries that have 
gathered evidence and are developing a national plan (Georgia), produced an investment case for 
elimination (South Africa), and obtained accurate data to inform the response (Scotland). 
Georgia: the development of a national plan 
Georgia was the first country in the WHO European region to set a hepatitis C elimination goal and 
develop a national plan for viral hepatitis tailored to the local context. Georgia’s significant 
experience with HIV prevention and control programs and the existing human and technical 
capacities to implement large-scale health programs facilitated the implementation of their national 
hepatitis C elimination program.38 An international Technical Advisory Group assisted with 
describing the local hepatitis C epidemiology and proposing strategies, objectives, and actions to 
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address gaps in advocacy and awareness, surveillance, harm reduction, blood safety, infection 
control, and evidence-based screening and linkage to care. Gilead Science provided direct-acting 
antiviral (DAA) therapy to Georgia at no cost after the elimination program commenced; reportedly, 
a key reason for their decision was the Georgian Government’s commitment to an elimination 
response. 
The program initially focused on increasing access to affordable diagnostics; providing free DAA 
treatment to persons with severe liver disease at highest-risk of hepatitis C-related mortality; and 
building capacity to achieve program goals of preventing transmission and eliminating the disease.39 
Initial obstacles included suboptimal alignment of program development and implementation, 
leading to bottlenecks in patient flow and wait lists.40 Training for healthcare workers was only 
provided after the program launched; however, doctors have subsequently received continuous 
technical support. 
The program has now expanded its scope to treat every person chronically infected with hepatitis C, 
as outlined in the “Strategic plan for the Elimination of Hepatitis C Virus in Georgia, 2016-2020”. 
Hepatitis C treatment services are provided at treatment centres located throughout the country 
and treatment decentralisation in harm reduction centres and primary care is ongoing. Patient out-
of-pocket fees for diagnostics and clinical monitoring are based on ability to pay. Georgia is working 
to integrate its hepatitis C elimination program into the overall health system, because this will 
benefit the management of other health problems such as HIV and tuberculosis.41 This is primarily 
being achieved via treatment decentralisation into primary care and harm reduction services. 
The implementation of the national action plan increased access to hepatitis C testing and linkage to 
care while driving improvements in monitoring and surveillance, infection control and prevention.38, 
41 The evaluation of harm reduction-based peer-supported hepatitis C treatment demonstrated 
excellent treatment uptake and retention in care among PWID based in Tbilisi.42 By January 2019, 
53,000 people had initiated treatment with the new DAAs, of whom almost 34,800 had already 
achieved hepatitis C cure (Figure 2.a). Remaining challenges relate to the marginalised status of 
PWID, with stigma and discrimination preventing PWID from accessing hepatitis C services. Punitive 
drug laws (such as criminal responsibility for personal drug use) challenge the effectiveness of harm 
reduction programs and lead to high rates of incarceration and hepatitis C transmission in prisons, 
where access to OST is limited. As well, as in other countries aiming for hepatitis C elimination, 
treatment numbers declined after the first two years of the program, with many people being 
unaware of their hepatitis C status or not commencing treatment. 
 
South Africa: The development of an investment case. 
South Africa’s National Action Plan 2017-2021 is one of the first examples of an investment case that 
combines tools for costing, impact modelling, cost-effectiveness analysis, and fiscal space analysis 
for scaled-up hepatitis B and hepatitis C disease control scenarios.43 The action plan was developed 
in collaboration with leading South African experts, Ministry of Health officials, and external 
specialists in global health policy and economics, who assessed cost and affordability, health impact 
and cost-effectiveness for four priority interventions: hepatitis B birth dose vaccination, prevention 
of MTCT and treatment for hepatitis B and C.  
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The model suggests expanded hepatitis B prevention and treatment for hepatitis B and C (using 
DAAs for the latter) is cost-effective and affordable in the South African context,43 noting that 
hepatitis B birth dose vaccination should be prioritised if funds are insufficient for the full 
implementation. The five-year Action Plan was estimated to cost US$270 million, with the “testing, 
care, and treatment” component being the most costly. Whilst this is a significant amount of money, 
seen against 5-year HIV expenditure, the cost of the Hepatitis Action Plan is estimated to be less 
than 4% of the projected HIV spend in South Africa.44 Integrating the action plan into the existing 
health system, particularly maternal and child health and HIV/AIDS services, was estimated to 
improve implementation feasibility.  
The modelling data suggests the initial five-year investment could avert an estimated 13,000 
hepatitis B-related deaths and 7,000 hepatitis C-related deaths. Moreover, a continued expansion of 
the treatment program beyond 2021 has the potential to avert 672,000 hepatitis B-infections and 
60,000 deaths averted from hepatitis C-related liver disease, which would put South Africa firmly on 
the path to achieve elimination by 2030 (Figure 2.b).43 
The multi-stakeholder approach used to develop an investment case for the cost-effectiveness and 
affordability of hepatitis control and elimination for South Africa provides a template for other 
countries.45 Implementation of the investment case-informed Viral Hepatitis Action Plan is expected 
to commence on 1st April 2019, with five priority interventions during the first year: (1) hepatitis B 
birth dose vaccination; (2) healthcare worker hepatitis screening, vaccination and training in viral 
hepatitis (3) increasing awareness, diagnosis and management of Hepatitis B virus (Tenofovir is on 
the Essential Medicine list); (4) registration of DAAs and price negotiations; (5) a comprehensive 
package of viral hepatitis services for key populations – men who have sex with men and people who 
use/inject drugs. 
Key obstacles to the response are a lack of funding being allocated to the Program due to fiscal 
constraints; a shortage of trained health workers; lack of knowledge about viral hepatitis in the 
general public; viral hepatitis-related stigma; limited access to harm reduction services; and punitive 
drug laws. There is a need to improve viral hepatitis services in other key populations, including 
prisoners, sex workers, and men who have sex with men. Moreover, DAAs are yet to be registered in 
South Africa due to administrative delays at the South African Health Products Regulatory Authority, 
preventing broader hepatitis C treatment scale-up. 
In order to address these obstacles, the South African Viral Hepatitis Working Group has established 
three subcommittees to oversee implementation of the hepatitis B birth dose vaccine, training of 
healthcare workers in conjunction with training on new HIV treatment regimens, and hepatitis C 
micro-elimination programs. 
 
Scotland: accurate data to inform the response 
In Scotland, advocates used political pressure and scientific evidence to raise awareness of the 
human impact of hepatitis C and its links to inequalities, which generated political consensus to 
support significant funding and evidence-based policy initiatives.46 Social and political recognition of 
the scale of the problem galvanised policymakers into action. Innovative strategies such as the 
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introduction of dried blood spot (DBS) sampling in community drug services made the model of viral 
hepatitis care more acceptable to affected communities and helped overcome barriers to testing.47 
Adopting a project management approach ensured achievable goal-setting and controlled ongoing 
cost. Substantial investment in a robust monitoring and surveillance system – combined with 
ambitious treatment targets – facilitated progress and demonstrated immediate impact, which 
helped to sustain momentum.48 Scotland’s response – the National Hepatitis C Action Plan – has 
been a phased one. Launched in 2006, Phase I focused on gathering evidence to inform and 
generate proposals for the development of hepatitis C services and identify the additional 
investment required. Subsequently, in Phase II the Scottish Government committed funds to 
substantially improve prevention (including increasing coverage of harm reduction services), 
diagnosis and treatment services and deliver evidence-based actions throughout the country for 
improved hepatitis C prevention and control (Figure 2.c). Since 2011, the Hepatitis C Action Plan has 
been integrated with other national policies within the Scottish Government’s Framework on Sexual 
Health and Blood Borne Viruses, which adopts a multi-agency outcomes-based approach with a 
strong focus on challenging inequalities.49, 50 
The national strategy to improve prevention, diagnosis and treatment services led to a significant 
decline in hepatitis C incidence, more new diagnoses, more people undergoing hepatitis C treatment 
and achieving cure, reductions in liver-related morbidity and mortality, and a decreased population 
prevalence of chronic hepatitis C.48, 51-53 Scotland’s example showcases the utility of evidence-based 
national hepatitis C strategies in reducing the financial and societal burden of the epidemic53, 54 and 
provides a working model for other countries to follow.  
Despite the progress made in improving harm reduction services in Scotland during the era of 
interferon-based treatment, the prevalence of hepatitis C infection had remained stubbornly high. 
The recent scale-up of DAA therapy to PWID is hoped to bring a treatment-as-prevention benefit.55 
While the roll-out of DBS testing was effective at diagnosing infection, a substantial minority of the 
infected population remains undiagnosed. It has proven difficult to fully engage general practitioners 
in case-finding initiatives, with awareness-raising campaigns having limited success.56, 57 However, it 
is hoped that the availability of DAAs within primary care and other community settings will increase 





Globally, nine out of 10 people living with viral hepatitis are unaware of their infection, 33 and lack of 
public knowledge is often compounded by viral hepatitis-related stigma and discrimination. 
Implementation of a viral hepatitis strategy should therefore include awareness-raising activities to 
generate demand for viral hepatitis care (e.g. through social media campaigns, such as in Brazil58) in 
conjunction with supportive laws, policy and guidelines that aim to reduce stigma and enable the 
establishment of community-focused responses.59 
Prevention activities should be implemented and scaled up to effectively eliminate viral hepatitis 
transmission. A highly effective hepatitis B vaccine has been available since the 1980s, and early 
immunisation plus the distribution of hepatitis B immunoglobulin (HBIg) to at-risk infants prevents 
perinatal transmission, as China has demonstrated.60 Harm reduction interventions, including NSPs 
and provision of OAT, cost-effectively reduce primary and reinfection incidence among PWID.61-63 
Iatrogenic transmission can be eliminated through routine screening of blood supply64 and 
implementation of safe infection practices (including reducing unnecessary injections, staff training 
and effective waste management),65 while simultaneously contributing to health systems 
strengthening.4, 66  
Finally, implementation of a viral hepatitis response must aim to optimise the viral hepatitis care 
cascade by substantially improving testing rates, linkage to care and treatment numbers. The case of 
Egypt (and Iceland, see Appendix 1) demonstrates that concerted efforts enable substantial 
advances towards the WHO targets of 90% of people diagnosed and 80% of eligible people 
treated.30, 67, 68 
Below are examples of implementation: raising awareness and stigma reduction (Brazil), investment 
in prevention (China), and investment in testing, linkage to care and treatment (Egypt). 
Brazil: raising awareness and stigma reduction 
Brazil, a middle-income country, has been providing universal access to antiretroviral therapy for HIV 
since 1996, driven by strong political will, multisectoral mobilisation and use of Trade Related 
Aspects of Intellectual Property Rights (TRIPS) flexibilities, and civil society engagement.69 It has 
championed the cause of viral hepatitis and advocated for an intensified global response for many 
years. Learning from its successes in reversing the trend of the HIV epidemic, Brazil established a 
national hepatitis program informed by up-to-date estimates of disease prevalence, international 
guidelines and cost-effectiveness in the Brazilian Unified Health System.58 Brazil invested in universal 
hepatitis B vaccination, increased capacity for hepatitis C testing in HIV services, expanded its 
laboratory network and set up a referral system for hepatitis patients. To reach the target 
population, the Ministry of Health conducted new public awareness and diagnosis campaigns using a 
variety of media with endorsement from civil society and the scientific community.58 
Brazil was able to obtain an unprecedented discount for an upper-middle-income country through 
price negotiations with originator pharmaceutical companies. Between 2015 and 2018 it provided 
treatment to nearly 90,000 people, and is expected to treat another 50,000 patients in 2019, largely 
thanks to the strong advocacy of civil society. 
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The remarkable process applied in Brazil was based on epidemiological data and scientific evidence, 
and motivated by its engagement with the SDGs, which may inspire other countries to identify ways 
to achieve these goals by 2030.58 Brazil has pledged to provide free hepatitis C treatment to 
everyone infected and is one of 12 countries on track to achieve hepatitis C elimination by 2030 
(Figure 3.a).30  
Despite this progress, geographical, social and economic disparities in Brazil challenge the provision 
of equitable service access across varied geographical regions. Brazil is working to improve diagnosis 
rates and mitigate losses to follow-up, resulting from the long delays between diagnosis and 
treatment initiation arising from small numbers of specialists who can provide DAA treatment.70 
China: Investment in prevention 
China is home to nearly one third of all people living with hepatitis B infection globally. HBsAg 
prevalence is estimated at 5.5%2 and hepatitis B causes over 300,000 deaths annually due to liver 
diseases.71 The implementation of a universal hepatitis B vaccination program for infants has 
reduced chronic hepatitis B incidence dramatically during the past two decades. The full 
implementation of a national program for the prevention of MTCT guarantees adequate supply of 
HBIg for at-risk newborns. Domestic procurement of the hepatitis B vaccine and auto-disable 
syringes ensures sustainable supply chains and stimulates regional industry and technology 
markets.72 
Driven by strong political commitment and with support from the Global Alliance on Vaccine and 
Immunization, including an investment of ~USD76 million to subsidise the hepatitis B catch-up 
vaccination program for 15 million children through public-private partnerships such as with Rotary 
and the ZeShan Foundation,73 multiple strategies were developed and implemented collaboratively 
(Figure 3.b). As a result, >95% of infants receive the hepatitis B vaccine within 24 hours of birth.74-77 
This program led to a nationwide catch-up vaccination drive for children up to the age of 15, 
reaching 68 million people over a 3-year period (2008–2011) (private communication). Between 
1992 and 2013, China’s efforts have prevented 90 million cases of chronic hepatitis B infection and 
24 million fewer people are carriers of the virus –a massive reduction in the global burden of viral 
hepatitis.72  
Although China has made considerable progress with hepatitis B, systemic obstacles to the 
elimination of MTCT remain. The physician-centred approach of the medical service infrastructure 
discourages affected pregnant women from seeking timely treatment, because physicians trained to 
provide treatment (i.e. obstetricians, gynaecologists, gastroenterologists and infectious disease 
specialists working in central hospitals) are often reluctant to do so. Moreover, China is yet to 
implement a comprehensive national strategy addressing its hepatitis C epidemic. Few DAAs have 
been approved and their high cost restricts inclusion in basic health insurance programs; 
consequently, DAA treatment is not universally available. Policy changes and education campaigns 




Egypt: testing, linkage to care and treatment 
Egypt has a very high burden of hepatitis C infection and disease, with approximately 7% of 
Egyptians aged 18–59 living with chronic hepatitis C infection in 2015. 78 This large reservoir of active 
infection and continued unsafe medical practices contribute to ongoing transmission; in 2016, an 
estimated 150,000 Egyptians were newly infected.79 
Egypt is committed to ending its generalised hepatitis C epidemic. It has developed one of the 
largest national programs for hepatitis C treatment.80 Egypt provides free and universal access to 
locally produced DAA treatment, as part of a national action plan for the prevention and control of 
viral hepatitis. To maximise efficiencies, the country has rolled out mass screening since October 
2018, providing direct linkage to hepatitis C care. Over six months, more than 49 million people were 
reached, of whom over 2 million were diagnosed as hepatitis C-antibody positive (in addition, >2.5 
million possible cases of diabetes and >10 million possible cases of hypertension were identified and 
referred for further assessment and management). Of hepatitis C patients linked to care and 
confirmed as ribonucleic acid (RNA) positive, 750,000 started treatment. 
By 2019, over 2.4 million Egyptians had been treated, and the country is on track to achieve WHO 
elimination targets in spite of its high hepatitis C prevalence (Figure 3.c).81, 82 Egypt’s response was 
facilitated by strong political will and government advocacy, effective price negotiations, removal of 
patent barriers on DAAs, and ability to produce DAAs locally.68, 83 
Despite great progress Egypt’s response is challenged by difficulties in capturing non-responders to 
treatment and lack of appropriate medications to initiate retreatment. Moreover, children under 12 
years old cannot be treated because the medications have not yet been approved for this age group. 
Finally, plans and strategies for surveillance to reliably capture whether hepatitis C elimination 
targets have been met are not fully developed. 
Integration 
 
The cost burden of viral hepatitis diagnostic tests and treatment – in particular the new DAA 
treatment for hepatitis C – challenges the feasibility and sustainability of effective viral hepatitis 
elimination activities. Unlike for other major communicable diseases such as HIV, tuberculosis and 
malaria, there is little funding available for viral hepatitis at an international level and most countries 
lack dedicated hepatitis budgets or programs.18 Although the private sector (such as pharmaceutical 
companies) and international funders and organisations are important actors in global elimination 
efforts, most funding will have to be mobilised from public, domestic sources to ensure the 
sustainability of viral hepatitis services as part of a broader effort to increase overall investments in 
health.29, 84, 85 Increasing investment in infrastructure and health service delivery (i.e. health systems 
strengthening) is not only a key enabler for viral hepatitis elimination but a requirement to reach the 
overarching SDG 3 for health and its target of universal health coverage.19 Ensuring that hepatitis 
services are integrated within these systems can reduce costs, compared to an isolated, non-
strategic approach,31 exemplified here in the case of Rwanda.  
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Integrating the viral response into the health system by utilising existing structures and trained 
workforces can save costs and generate efficiencies, as well as maximising access to services for key 
risk populations.86 For example conducting viral hepatitis testing at HIV services is likely to yield high 
diagnosis rates because people living with HIV have a higher risk of hepatitis B or hepatitis C co-
infection, and may improve their engagement in care.87 However, it is important to look beyond 
integrating the response into HIV programs, because further opportunities exist to broaden the viral 
hepatitis response by integrating it within tuberculosis, maternal and child health, and diabetes 
programs. Also such an approach may not be useful in countries with generalised epidemics (such as 
China and Egypt) that require population-based approaches to testing and treatment.   
Even when the response is integrated within the broader health system, there will be extra costs due 
to the need to expand services and to increase staffing levels to accommodate the increased activity. 
For example, additional time is needed to administer a hepatitis B vaccine or to provide post-test 
counselling for positive test results.88 Due to concerns about extra costs and workload, efforts to 
integrate viral hepatitis responses into existing systems and platforms may receive substantial 
pushback, particularly initially. However, there is no evidence to support the notion that introducing 
viral hepatitis care into these systems causes existing structures to collapse.89  
Moreover, multiple countries have been able to make treatment accessible to the broader 
population by successfully negotiating with patent holders (e.g. Australia), making use of patent 
licenses either available directly from the patent owner or those held by the Medicines Patent Pool 
(e.g. Rwanda)90, or using TRIPS flexibilities to circumvent patent barriers to accessing lower priced 
generic DAAs (e.g. Malaysia, see Table 4 and Appendix).91  
Below are examples of integration: health systems strengthening (Rwanda) and investment and 
financing for sustainability (Australia). Importantly, the health systems in both countries have coped 
with this considerable scale up of treatment and care. 
Rwanda: expanding on universal health coverage 
Rwanda is a low-income country that is using a public health framework for hepatitis control and 
care to progress on its aim to achieve universal health coverage.  
The country has made tremendous gains in maternal and child health, malaria, tuberculosis and HIV 
outcomes. The Rwandan Government now invests major resources in viral hepatitis, using 
programmatic steps that form a blueprint for other low-income countries in the region.92 Key 
elements of Rwanda’s program for viral hepatitis prevention and treatment include: 
 Simplified treatment algorithms not requiring hepatitis C genotype or hepatitis B viral load 
and largely able to be delivered by nurses at health centre level  
 Selective partnerships and preferred suppliers to drive down price, consolidate the supply 
chain and streamline diagnostic platforms to avoid siloed approaches to healthcare93 
 Study of necessary resources for efficient implementation  
 Development of a training program for health staff  
 Development, funding and implementation of birth dose vaccination for hepatitis B.  
To ascertain feasibility and ensure financing for sustainability, a national operational plan was 
developed to demonstrate priority-setting of key activities and provide costing estimates for 
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different levels of coverage of screening, diagnosis, and treatment of both hepatitis B and C.92 
Several initiatives were used to secure funding, including support from international donors, in 
particular the Clinton Health Access Initiative. Rwanda has a voluntary licensing agreement for DAAs 
and is therefore able to producre medication at reduced cost (approx. US$ 560 in 2017).68, 92 
Rwanda’s Essential Medicines List includes generic hepatitis B medicines treatment; this is 
subsidised by government for people with HIV coinfection. All major private health insurance 
companies (as well as military medical insurance) reimburse for the cost of DAAs, and the Rwanda 
social security board covers 85% of the cost. Ultimately, the aim is to provide reimbursement for 
hepatitis C diagnostics and treatment by the community-based health insurance scheme.92 As of 
June 2017, 2,500 patients had been treated with DAAs and treatment for 9,000 additional patients 
had been procured (Figure 4.a). Rwanda aims to establish treatment capacity at all 48 district 
hospitals countrywide by 2020.  
Major ongoing barriers to addressing viral hepatitis in Rwanda include the lower awareness of, and 
priority given to, viral hepatitis compared to other infectious diseases (e.g. malaria and HIV) and the 
competing priorities for limited public-sector health funding. A prior strategy (from 2011) that failed 
and has since been abandoned was to develop local viral hepatitis treatment guidelines based upon 
international consensus guidelines, without sufficient attention to the resources required for 
implementation (including particularly laboratory testing and availability of medications) or the skills 
and experience required of clinicians. These guidelines thus lacked local contextualisation and 
recommended unavailable or unaffordable management; consequently, they were impractical and 
did not influence daily clinical practice greatly. 
 
Australia: a multipronged approach to elimination 
In 1999, Australia was one of the first countries to implement and subsequently refine their national 
hepatitis C strategies and has since then become a best practice model for hepatitis C elimination. 
Key to Australia’s response, including achieving universal treatment access (described below), has 
been strong community advocacy, health research, health sector and political leadership that foster 
continued commitment to the WHO 2030 elimination targets, including a timely response to new 
challenges.94 Australia has had a long and sustained harm reduction approach to injecting drug use, 
with engagement of civil society, the health sector and government. This is beneficial in reducing 
bloodborne virus transmission and cultivates a point of engagement with PWID in providing health 
and social services. 61-63, 95 Strong engagement with PWID is crucial to Australia’s response. 
By negotiating a volume-based, risk-sharing agreement with originator pharmaceutical companies 
and committing over AUD1 billion to the purchase of DAAs between March 2016 and February 2021, 
Australia obtained major discounts on drug list prices and as a consequence limited its expenditure. 
With no cap on treatment numbers,96 there is an incentive to diagnose and treat as many people as 
possible to maximise Australia’s investment and its public health benefits. This provides an enabling 
environment to prioritise high-prevalence groups with ongoing risks for treatment, such as PWID 
and prisoners, necessary to achieve hepatitis C elimination. In addition, all registered medical 
practitioners are able to prescribe DAA therapy, enabling more convenient, patient-centred care. In 
Australia, close collaboration between people living with hepatitis C, community organisations, 
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clinicians and policymakers facilitated improved access to diagnosis and treatment scale-up (Figure 
4.b).  
Australia aims to treat around 15,000 to 20,000 hepatitis C patients per year, to reach the WHO 
target to eliminate viral hepatitis as a major public health threat by 2030. This early commitment to 
achieving elimination and provide unrestricted treatment access enabled rapid treatment uptake 
during the first two years of DAA availability.94 Between March 2016 and late 2018, over 70,000 
patients (around 30% of all infected Australians) were treated. The proportion of individuals 
prescribed DAA treatment by general practitioners increased from 8% in March 2016 to 39% in June 
2017.97 With the successful implementation of its hepatitis C strategy – a global benchmark for best 
practice98 – Australia is on track to achieve elimination by 2030.99  
Of concern in Australia is the continuing drop off in the number of patients undergoing screening 
and confirmatory testing and treatment since March 2016.97 Whilst treatment numbers have been 
sufficient to maintain the elimination targets, further decline could put the elimination effort at risk. 
The decline in treatment numbers demonstrates that universal availability of DAA treatment alone is 
not enough to improve access to diagnosis and retention in care. Continued political commitment 
and policy and health system interventions are needed to facilitate treatment access for key 




The broader benefits of investing in the elimination of viral hepatitis – including progressing on the 
SDGs - are increasingly being recognised. Countries with different income levels, public health 
infrastructures and policy environments are effectively responding to their respective epidemics.  
Attaining the viral hepatitis elimination targets set by the global community in 2016 is achievable but 
also highly ambitious and comes with considerable challenges (see Appendix, Table 6). These should 
not be ignored, but instead considered and addressed both at a global level and within the local 
context to invigorate and maintain national elimination efforts. Gathering sufficient funds to finance 
viral hepatitis programs continues to be difficult among competing health priorities and budget 
constraints. Not all countries currently benefit from generic competition, with heavily burdened 
middle-income countries (e.g. China, Malaysia, Thailand) struggling to afford higher drug prices. A 
further obstacle is the increasing cost of diagnostics; for example, in Egypt expenditure on 
diagnostics now exceeds that on hepatitis C treatment.70 There are few WHO prequalified point-of-
care viral hepatitis tests and little production of low-cost high-quality generic tests. In many low-
income countries, strengthening primary health care systems for maternal and child health, 
developing laboratory capacity, and improving weak registration and procurement systems for 
essential medicines is an ongoing challenge. For hepatitis B, cold chain barriers to vaccination 
including birth dose delivery exist, and whilst the controlled temperature chain presents a cost-
effective alternative that could vastly improve coverage100 it is yet to be broadly adopted.  
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Even in countries such as Australia, where there is close collaboration between community, 
government and health practitioners to guide implementation, elimination cannot be guaranteed 
because many patients remain undiagnosed and/or do not access treatment.97, 101, 102 Identification 
of sufficient numbers of infected patients needing treatment remains a challenge globally; 
meanwhile, in countries where scale-up of a viral hepatitis response is pending, demand for viral 
hepatitis testing and treatment can outstrip available testing and treatment facilities,89 creating 
bottlenecks within the care cascade leading to losses to follow-up. High levels of stigma, 
discrimination, social marginalisation and legal impediments imposed on key populations at risk or 
infected with viral hepatitis (e.g. PWID, prisoners, men who have sex with men, sex workers) is a 
major issue preventing engagement in care and service access87 and in many countries legal 
protections remain insufficient.70  The impact of regressive policies and laws on the elimination 
response cannot be underestimated. 
The country case studies presented here demonstrate that major gains are possible in spite of these 
challenges – across various epidemic profiles, within a diverse range of resource constraints and 
within relatively short time frames. The case studies illustrate that political will and commitment, 
civil society advocacy, donor support and community acceptance are crucial and can make a 
difference. From concerted screening efforts in Egypt and using innovative approaches to increase 
hepatitis C testing in Scotland, to building local investment cases in South Africa, to integrating viral 
hepatitis services into existing health infrastructure in Brazil and Rwanda, these pioneers provide 
important models for other countries to follow. In all countries multi-stakeholder engagement of 
national and international experts, civil society organisations and affected communities form critical 
components across the three pillars of evidence-gathering and planning, implementation and 
integration.  
On a global level, civil society bodies such as the World Hepatitis Alliance are instrumental in 
generating pressure on governments and international organisations, providing an evidence-based 
approach to the response.88 Locally, robust evidence and civil society advocacy helped to achieve 
political commitment and facilitated the development of national plans. Collaboration and 
cooperation between civil society, the pharmaceutical industry and government smoothed the 
introduction of prevention and control programs. Such unified, evidence-informed strategies at the 
political and technical levels are crucial to attract and sustain commitment and financing. Learnings 
from these country examples and other local projects demonstrating the feasibility of elimination 
(e.g. micro-elimination projects36, 103) can help persuade policymakers in other countries to support 
viral hepatitis prevention and control plans. In-country and global advocacy must be maintained to 
keep viral hepatitis high on the political agenda.88 
Conclusion  
 
At the 2016 World Health Assembly, the global community uniformly endorsed the unique 
opportunity to eliminate viral hepatitis as a public health threat. Although an ambitious goal, 
technological advancements have made it scientifically feasible and increasing recognition of the 
public health threat posed by viral hepatitis provides the grounds for substantial political and 
societal support. The broader benefits of investing in the elimination of viral hepatitis – including 
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progress on the Agenda for Sustainable Development – are now well recognised. Sustaining political 
momentum will be critical if elimination efforts are to be successful and more countries will need to 
take action if global elimination of viral hepatitis is to be achieved. Looking to existing approaches 
that address viral hepatitis can facilitate political support, because they demonstrate that investing 
in viral hepatitis is cost-effective and can be made affordable, provide multiple economic benefits, 
and above all alleviate the human burden of the epidemic. The case studies presented in this paper 
provide clear and feasible examples of successful approaches taken by low-, middle- and high-
income countries with diverse epidemics of hepatitis B and C to achieve the WHO 2030 viral 
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Table 1: Viral hepatitis service coverage and impact targets 
Target area Baseline 2015 2020 Target 2030 Target 
Service coverage targets 
Hepatitis B virus vaccination: 
childhood vaccine coverage (third 
dose coverage) 
82% of infants 90% 90% 
Prevention of hepatitis B virus 
mother-to-child transmission: 
hepatitis B virus birth-dose coverage 
or other approach to prevent 
mother-to-child transmission 
38% 50% 90% 
Blood safety: donations screened 
with quality assurance 
89% 95% 100% 
Injection safety: use of engineered 
devices 
5% 50% 90% 
Sterile needle/syringe set distributed 
per person per year for PWID 
20 200 300 
Viral hepatitis B and C diagnosis 
(coverage %) 
<5% of chronic hepatitis 
infections diagnosed 
30% 90% 
Viral hepatitis B and C treatment 
(coverage %) 
<1% receiving treatment 3 million 80% eligible 
treated 
Impact targets 
Incidence: new cases of viral 
hepatitis B and C infections 
Between 6 and 10 million 
infections are reduced to 0.9 
million infections by 2030 (95% 
declined in hepatitis B virus 
infections, 80% decline in 
hepatitis C virus infections) 
30% reduction  
 
(equivalent to 1% 











Mortality: Viral hepatitis B and C 
deaths 
1.4 million deaths reduced to less 
than 500 000 by 2030 (65% for 
both viral hepatitis B and C) 
10% reduction 65% 
reduction 



















97.55 12.21 24.6 
Life expectancy at 
birth (years) 
73 63 79 76 76 71 67 83 

































































Table 3: National activities and country examples aimed at elimination of viral hepatitis 




National hepatitis plan (addressing 
hepatitis B, hepatitis C or both) 
 
Georgia, Australia, Brazil, China, 
Egypt, Iceland, Malaysia, Portugal, 
Scotland, South Africa 
Local investment case South Africa, Rwanda 
Accurate data to inform the response 
(Surveillance and Monitoring) 
 
Scotland, Portugal, Brazil, Egypt, 
Georgia, Iceland, Pakistan, South 
Africa 
Implementation  Raising awareness and stigma 
reduction 
 
Brazil, Australia, , China, Egypt, 
Iceland, Malaysia, Portugal, 
Pakistan 
Investment in prevention 
 
China, Fiji, Pakistan, Australia, 
Brazil, Iceland, Georgia, Malaysia, 
Portugal, Scotland 
Testing, linkage to care and 
treatment 
 
Egypt, Australia, China, Georgia, 
Iceland, Malaysia, Portugal, 
Scotland, South Africa 
Integration Health Systems Strengthening 
 
Rwanda, Brazil, Fiji, Georgia, 
Malaysia, South Africa 
Investment and financing for 
sustainability 
Australia, China, Iceland, Malaysia, 
Rwanda 






Table 4: Hepatitis B vaccination coverage and procurement status of hepatitis C medicines 
Country Hepatitis B vaccination coverage 
(2019)
77 










Voluntary license (VL) or 
Compulsory/government-







Australia 94% 91% Yes - No No 
Brazil 86% 76% Yes No No No  
China 99% 96% Yes No No No 
Egypt 95% 13% Yes VL Yes Yes 
Fiji 93% 95% No VL No No 
Georgia 92% 94% Yes  VL No Yes 
Iceland * * Yes - No Yes 
Malaysia 98% 88% Yes CL and VL No No 
Pakistan 86% <1% Yes  VL Yes Yes 
Portugal 98% 97% Yes - No No 





 n/a Yes  
VL 
No No 
Rwanda 98% 0% Yes VL No Yes 
*Estimates of hepatitis B vaccination coverage were produced only for countries with universal birth dose policy
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